<code id='D7E2B8C690'></code><style id='D7E2B8C690'></style>
    • <acronym id='D7E2B8C690'></acronym>
      <center id='D7E2B8C690'><center id='D7E2B8C690'><tfoot id='D7E2B8C690'></tfoot></center><abbr id='D7E2B8C690'><dir id='D7E2B8C690'><tfoot id='D7E2B8C690'></tfoot><noframes id='D7E2B8C690'>

    • <optgroup id='D7E2B8C690'><strike id='D7E2B8C690'><sup id='D7E2B8C690'></sup></strike><code id='D7E2B8C690'></code></optgroup>
        1. <b id='D7E2B8C690'><label id='D7E2B8C690'><select id='D7E2B8C690'><dt id='D7E2B8C690'><span id='D7E2B8C690'></span></dt></select></label></b><u id='D7E2B8C690'></u>
          <i id='D7E2B8C690'><strike id='D7E2B8C690'><tt id='D7E2B8C690'><pre id='D7E2B8C690'></pre></tt></strike></i>

          
          WSS
          Alnylam headquarters
          Kristoffer Tripplaar/Sipa USA/AP

          A group of advisers to the Food and Drug Administration voted in favor of Alnylam Pharmaceuticals’ treatment for a debilitating heart disease Wednesday, but only after a day-long debate challenging whether the drug’s modest observed effects were actually meaningful for patients.

          The group of independent experts voted 9-3 that the benefits of Alnylam’s drug, called patisiran, outweighed its risks for patients with ATTR-CM, a progressive disease that leads to fatal heart failure if left untreated. The FDA, which is not required to follow the advice of advisers, is expected to make a final decision on patisiran by Oct. 8.

          advertisement

          “It’s like a light wind blowing in favor of patisiran over placebo,” said David Cella, a neurologist at the Northwestern University Feinberg School of Medicine who voted in favor of patisiran. David Moliterno, a cardiologist at the University of Kentucky, added that “the good news in this story is that while there may be a small benefit, it doesn’t look like there’s a signal for harm.”

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          Leave your comment

          Please enter your name
          Please enter your comment

          fashion